Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

Research output: Contribution to journalArticleAcademicpeer-review

46 Citations (Scopus)


With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
Original languageUndefined/Unknown
Pages (from-to)13-18
Number of pages6
JournalBritish Journal of Cancer
Issue number1
Publication statusPublished - 2009

Cite this